"When asked what success in Phase 2 would mean, Lesley said: "If there are early signs of response, it will move right into registration. As you can tell by the investment they've made it could easily be ran by both companies or maybe their company might take it over". BANG! There it is. A potential buy-out of Herr-Vax. At least that's the way I read it."
I just watched the Proactive Investors video and it seemed to me the comment was in relation to the study, not a buyout of HER-Vaxx. The benefit of their company taking over the trial is that they would pay for it instead of Imugene. Remember, Imugene is very promiscuous and will be running combo trials with other companies and aren't looking to settle down with a single partner. "This is one of hopefully many."
No worries. In the Proactive Investors video LC described the design of the trial pretty much how I thought it would go. It's a very exciting approach for them to look at what's going on in the samples after treatment. Hopefully all that they get to look at is dead tumours killed by HER-Vaxx.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)